{"entity":{"id":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","kind":"paper","name":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","aka":[],"tldr":"The combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib shrank tumours in about a third of women with recurrent low-grade serous ovarian cancer and in 44 percent of those with KRAS mutations, leading to the first approval specific to this disease.","summary":"Phase 2 study of 115 patients with recurrent low-grade serous ovarian cancer treated with avutometinib alone or with defactinib; the combination was selected for expansion.\n\nIn the combination arm, objective response was 31 percent overall and 44 percent in KRAS-mutant tumours (17 percent in KRAS wild-type), with median duration of response of 31 months and median progression-free survival of 12.9 months overall; toxicity included creatine kinase elevation, nausea and rash.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2025","url":"https://doi.org/10.1200/JCO-25-00112"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40644648/"}],"tags":[],"related":[],"cancers":["low-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ramp-201"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2025,"doi":"10.1200/JCO-25-00112","pmid":"40644648","authors":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al.","paperType":"observational","findings":["Objective response 31 percent overall; 44 percent in KRAS-mutant and 17 percent in KRAS wild-type tumours.","Median duration of response 31.1 months."],"whatItMeans":"Avutometinib plus defactinib is approved for KRAS-mutant recurrent low-grade serous ovarian cancer, making KRAS testing a routine part of managing the disease; RAMP 301 is comparing it with standard therapy.","caveats":["Single-arm; approval was accelerated pending the randomised RAMP 301 trial."],"changedPractice":true,"participants":115},"route":"/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/","neighbours":{"cancer":[{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/"}],"trial":[{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}